Therapeutic potential of antagomiRs in haematological and oncological neoplasms

Area of Science:

• Oncology
• Molecular Biology
• RNA Therapeutics

Background:

• MicroRNAs (miRNAs) play a crucial role in human cancers by regulating post-transcriptional processes.
• Dysregulated miRNAs, known as oncomiRs, are implicated in cancer initiation, progression, invasion, and metastasis.
• Databases are actively collecting information on small RNA fragments involved in oncogenesis.

Purpose of the Study:

• To review and consolidate key literature findings on antagomiRs in oncology.
• To demonstrate the therapeutic potential of antagomiRs as effective anti-cancer compounds.
• To highlight antagomiRs as specific antisense oligonucleotides that antagonize single or multiple miRNAs.

Main Methods:

• Analysis of various antagomiR delivery systems, including peptide or locked nucleic acids.
• Evaluation of miRNA sponges and antagomiRs conjugated to plasmid or lentiviral vectors.
• Review of strategies to mitigate the high immunogenicity of antagomiRs for clinical application.

Main Results:

• AntagomiRs have demonstrated effectiveness across a wide range of tumor types.
• Various delivery methods, such as peptide conjugates and vector-based systems, show promise.
• Research is actively addressing the challenge of antagomir immunogenicity to facilitate clinical use.

Conclusions:

• AntagomiRs represent a promising therapeutic strategy for cancer treatment.
• These molecules offer precise targeting of molecular pathways involved in tumor growth.
• Further development of antagomiRs could lead to novel anti-cancer drugs with high efficacy and low toxicity.